Embracing Future Holdings Limited (8YY.SI) reported QQ2 2025 results with marginal revenue growth but persistent profitability headwinds. Revenue stood at SGD 878,500 in Q2 2025, yielding a gross profit of SGD 248,000 and a gross margin of 28.2%. The quarter delivered an operating loss of SGD 98,000 and a net loss of SGD 312,500, translating to a net income margin of -35.6% and an EBITDA of -SGD 303,000. The company continues to exhibit thin operating leverage against a high fixed cost base, reflected in an operating expense of SGD 346,000 and cost of revenue SGD 630,500. The liquidity profile remains constrained, with a current ratio of 0.58 and a cash ratio of 0.21, underscoring working capital and funding considerations as the company scales its precision diagnostics platform, including the ClearCell FX1 system and related services. Management has signaled ongoing strategic repositioning via a June 2025 name change and expanded multi-regional reach, but there is no formal guidance issued for QQ3/Q4 2025 in the provided data. Investors should monitor top-line growth catalysts, cost discipline, working capital management, and any forthcoming strategic updates tied to product adoption, reimbursement dynamics, and geography expansion.